Cochlear Limited (CHEOF)
OTCMKTS · Delayed Price · Currency is USD
175.01
0.00 (0.00%)
At close: Dec 24, 2025
Cochlear Revenue
In the fiscal year ending June 30, 2025, Cochlear had annual revenue of 2.34B AUD with 4.81% growth. Cochlear had revenue of 1.17B in the half year ending June 30, 2025, with 11.46% growth.
Revenue
2.34B AUD
Revenue Growth
+4.81%
P/S Ratio
7.48
Revenue / Employee
426.02K AUD
Employees
5,500
Market Cap
11.50B USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 2.34B | 107.50M | 4.81% |
| Jun 30, 2024 | 2.24B | 299.50M | 15.47% |
| Jun 30, 2023 | 1.94B | 287.80M | 17.46% |
| Jun 30, 2022 | 1.65B | 150.70M | 10.06% |
| Jun 30, 2021 | 1.50B | 177.00M | 13.40% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Cochlear News
- 18 days ago - MRI 3T Cochlear Implant Market Poised for 9.96% CAGR Growth, North America Leads - GlobeNewsWire
- 23 days ago - Saluda Medical shares sink in worst ASX debut in decades - The Australian Financial Review
- 24 days ago - MED-EL Cochlear Implant Becomes First FDA-Approved Option for Children Seven Months and Older - Business Wire
- 25 days ago - Saluda Medical set for $775m ASX debut - The Australian Financial Review
- 2 months ago - Brokers throw open $125m Epiminder IPO book; Cochlear in for $10m - The Australian Financial Review
- 4 months ago - Cochlear reports FY results - Seeking Alpha
- 4 months ago - Cochlear Ltd (CHEOF) (FY25) Earnings Call Highlights: Navigating Growth and Challenges - GuruFocus
- 4 months ago - Cochlear CEO depends on built-up inventory as some export licenses lag - CNBC